Result of AGM

RNS Number : 9033Q

Kanabo Group PLC

30 June 2022

 

Kanabo Group Plc.

Result of Annual General Meeting

Kanabo Group Plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below:

		Chairman of the meeting FOR		Chairman of the meeting AGAINST		Total Votes Cast	ABSTAIN
Resolution		No. of shares	%	No. of shares	%
1	Receive Financial Statements	115,542,133	99.75451	284,339	0.245487	115,826,472	142,706
2	Approve the Directors' Remuneration Report	115,458,280	99.69236	356,288	0.307637	115,814,568	154,610
3	Approve the re-appointment of the auditors and authorize the directors to determine the Auditors' Remuneration	115,553,226	99.75257	286,620	0.247428	115,839,846	129,332
4	Re-elect Andrew Morrison	113,469,744	97.99032	2,327,150	2.009683	115,796,894	172,284
5	Re-elect Avihu Israel Tamir	115,502,424	99.74567	294,510	0.254333	115,796,934	172,244
6	Re-elect David Tsur	115,508,799	99.75078	288,595	0.249224	115,797,394	171,784
7	Elect Daniel Poulter	115,509,839	99.75164	287,595	0.24836	115,797,434	171,744
8	Elect Gil Efron	115,509,839	99.75164	287,595	0.24836	115,797,434	171,744
9	Authorise the directors to allot securities	115,468,984	99.72081	323,278	0.279188	115,792,262	176,916
10*	Authorise the directors to allot Equity Securities	115,469,484	99.72081	323,278	0.279187	115,792,762	176,416

* Special Resolution

NOTES:

Votes "For" and "Against" are expressed as a percentage of votes received.

For further information, please visit http://www.kanabogroup.com/ or https://www.voxmarkets.co.uk/listings/LON/KNB or contact the following:

Kanabo Group Plc	Via Vox Markets
Avihu Tamir, CEO
Peterhouse Capital Ltd (Financial Adviser)	Tel: [phone]
Eran Zucker / Lauren Riley Peterhouse Capital Ltd (Corporate Broker) Lucy Williams / Charles Goodfellow Duncan Vasey / Martin Lampshire
Vox Markets (Investor Relations)	[e-mail]
Kat Perez	[e-mail]

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers.

The Company has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.

 

END

 

 

RAGEASKEDSKAEFA